LNSR
LENSAR Inc
NASDAQ: LNSR · HEALTHCARE · MEDICAL DEVICES
$5.83
+0.00% today
Updated 2026-06-03
Market cap
$67.78M
P/E ratio
—
P/S ratio
1.18x
EPS (TTM)
$-0.55
Dividend yield
—
52W range
$5 – $13
Volume
0.1M
WallStSmart proprietary scores
53
out of 100
Grade: C
Hold
Investment rating
4.7
Growth
C6.0
Quality
B8.0
Profitability
A4.0
Valuation
C2/9
Piotroski F-Score
Weak
-3.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$8.50
+45.80%
12-Month target
—
—
Intrinsic (DCF)
$6.71
Margin of safety
-85.10%
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 50.90% — above average
+ ROE 36.20% — strong efficiency
+ Debt/equity 0.10x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -3.69 — distress zone
- Negative free cash flow $-4.27M
- Revenue declining -5.20% QoQ
- 85.10% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $35.36M | $42.16M | $53.49M | $58.44M | $57.70M |
| Net income | $-19.91M | $-14.38M | $-31.40M | $-34.28M | $36.33M |
| EPS | — | — | — | — | $-0.55 |
| Free cash flow | $-14.97M | $-9.89M | $-2.43M | $-14.91M | $-4.27M |
| Profit margin | -56.32% | -34.11% | -58.71% | -58.66% | 50.90% |
Peer comparison
Smart narrative
LENSAR Inc trades at $5.83. Our Smart Value Score of 53/100 indicates the stock is fair. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -3.69, it sits in the distress. TTM revenue stands at $57.70M. with profit margins at 50.90%. Our DCF model estimates intrinsic value at $6.71.
Frequently asked questions
What is LENSAR Inc's stock price?
LENSAR Inc (LNSR) trades at $5.83, on a P/S of 1.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is LENSAR Inc overvalued?
LENSAR Inc carries a Smart Value Score of 53/100 (Grade C), which we rate Hold. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $6.71 against the $5.83 price, so on cash flow terms the market is paying a premium for LENSAR Inc's growth. The Hold rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of LENSAR Inc (LNSR)?
The 12-month analyst consensus target is $8.50, about 45.8% above the current $5.83. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of LENSAR Inc (LNSR)?
Our DCF model estimates intrinsic value at $6.71, a -85.1% margin of safety versus today's $5.83. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is LENSAR Inc's revenue?
LENSAR Inc's trailing twelve-month revenue is $57.70M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
LENSAR Inc's Altman Z-Score is -3.69, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.18x
ROE36.20%
Beta0.87
50D MA$5.69
200D MA$10.13
Shares out0.01B
Float0.01B
Short ratio—
Avg volume0.1M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—